Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366774 | 1.00 | NOS1 (0.36) | NOS1ALOX15PTPN6AXLMETAP2 | |
| SCHEMBL22806465 | 0.89 | NOS1 (0.35) | NOS1ALOX15AXLMETAP2IDO1 | |
| SCHEMBL29363726 | 0.89 | NOS1 (0.35) | NOS1ALOX15AXLMETAP2IDO1 | |
| SCHEMBL30975376 | 0.72 | NOS1 (0.34) | NOS1ALOX15PTPN6AXLMETAP2 | |
| SCHEMBL22489490 | 0.72 | NOS1 (0.38) | NOS1ALOX15PTPN6AXLMETAP2 | |
| SCHEMBL19995841 | 0.72 | NOS1 (0.38) | NOS1ALOX15PTPN6AXLMETAP2 | |
| SCHEMBL30641268 | 0.72 | NOS1 (0.34) | NOS1ALOX15PTPN6AXLMETAP2 | |
| SCHEMBL22804796 | 0.72 | NOS1 (0.40) | NOS1ALOX15AXLMETAP2IDO1 | |
| SCHEMBL29366451 | 0.72 | NOS1 (0.40) | NOS1ALOX15AXLMETAP2IDO1 | |
| SCHEMBL29860402 | 0.69 | NOS1 (0.46) | NOS1ALOX15PTPN6AXLMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |